Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204827 | 1.00 | EPHX2 (0.48) | EPHX2NR1H4TRPV1MEN1PKM | |
| SCHEMBL2205140 | 1.00 | EPHX2 (0.48) | EPHX2NR1H4TRPV1MEN1PKM | |
| SCHEMBL4673169 | 0.95 | EPHX2 (0.44) | EPHX2NR1H4TRPV1MEN1PKM | |
| SCHEMBL2207528 | 0.86 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL2207527 | 0.86 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL2208382 | 0.86 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL2205850 | 0.85 | EPHX2 (0.44) | EPHX2MEN1KMT2A | |
| SCHEMBL4620004 | 0.84 | EPHX2 (0.41) | EPHX2NR1H4TRPV1 | |
| SCHEMBL4619951 | 0.84 | EPHX2 (0.41) | EPHX2NR1H4TRPV1 | |
| SCHEMBL2210571 | 0.84 | ALDH1A1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981883-B2 | Substituted spiro-compounds and the use thereof for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-07-19 | — | — | US | claimed |
| US-20090275628-A1 | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | claimed |
| US-7981883-B2 | Substituted spiro-compounds and the use thereof for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20090275628-A1 | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275628-A1 | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments | REN, PKD1, PKD2 | EPHX2 1541/4885NR1H4 60/4885TRPV1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.